Toxicities associated with immunotherapies for hematologic malignancies

Publication date: Available online 28 March 2018 Source:Best Practice & Research Clinical Haematology Author(s): Mark B. Leick, Marcela V. Maus Immunotherapy has generated tremendous hope for patients with cancer that is refractory to standard approaches. Hematologic malignancies have taken the lead in harnessing the most recent advances in cell-based immunotherapies, such as CAR T cells, and some patients have achieved durable remissions. However, these T-cell-engaging therapies are associated with a new set of toxicities which need to be managed by caretakers, oncologists, nurses, and healthcare staff. In this review we provide an overview of the toxicity of some of these revolutionary agents including bispecific T cell engagers, checkpoint inhibitors, chimeric antigen receptor T-cells.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research